missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CX3CL1 Monoclonal Antibody (4C5)
Description
CX3CL1 Monoclonal Antibody for Western Blot, ELISA
Chemokines are a family of proteins associated with the trafficking of leukocytes in immune surveillance and inflammatory cell recruitment. They are classified based on the positions of key cysteine residues. CX3CL1 is a CX3C chemokine known to induce adhesion and migration of leukocytes mediated by a membrane-bound and soluble form respectively. Recent experiments have shown that CX3CL1 can suppress the production of nitrous oxide, interleukin-6, and TNF-a in activated microglia and neuronal cells, suggesting that it may act as an intrinsic inhibitor against neurotoxicity by activated microglia. Its receptor, CX3CR1, also functions as a co-receptor for HIV-1 and HIV-2 envelope fusion and virus infection, which can be inhibited by CX3CL1.
Specifications
Specifications
| Antigen | CX3CL1 |
| Applications | ELISA, Western Blot |
| Classification | Monoclonal |
| Clone | 4C5 |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 1mg/mL BSA, 50% glycerol and 0.05% sodium azide |
| Gene | Cx3cl1 |
| Gene Accession No. | O35188, P78423 |
| Gene Alias | A-152E5.2; AB030188; ABCD-3; Acc1; AI848747; C3Xkine; chemokine (C-X3-C motif) ligand 1; CX3C; CX3C membrane-anchored chemokine; C-X3-C motif chemokine 1; C-X3-C motif chemokine ligand 1; Cx3cl1; CXC3; CXC3C; D8Bwg0439e; Fkn; Fractalkine; neurotactin; NTN; NTT; Processed fractalkine; SCYD1; small inducible cytokine subfamily D (Cys-X3-Cys), member 1 (fractalkine, neurotactin); small inducible cytokine subfamily D (Cys-X3-Cys), member-1; small inducible cytokine subfamily D, 1; small-inducible cytokine D1 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?